Cellceutix Corp. (CTIX.OB) Signs Agreement for Kevetrin™ API
Cellceutix Corp., an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical needs, recently announced that the company has signed an agreement with Girindus America, Inc. to manufacture the active pharmaceutical ingredient of Kevetrin™. Cellceutix plans to use the active ingredient for toxicology studies and Phase 1 human trials. Although the terms of the agreement were not disclosed, Kevetrin™ is being developed to treat certain cancers and the company has recently reported encouraging results in animal models of drug resistant lung cancers. Additional information regarding the company’s progress and results can be found…